Drugs such as pemafibrate, metformin, and GLP-1 agonists, classified as PPARα-related drugs, have exhibited effectiveness and safety in clinical studies by reducing lipid and glucose levels in patients with diabetes [98]. This evidence concerns the gene GCG and diabetes mellitus.